Kai Thede

This inventor holds 34 USPTO granted patents and 24 published patent applications, plus 4 CIPO patents and 19 EPO patents, primarily in Macrocyclic Indole Derivatives. Top assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property Gmbh. Active years: 2009-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kai Thede. Retrieved from https://idiyas.com/inventor/kai-thede

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 34 (Patent Applications = 24)

% Patents Active = 55.9

CIPO Patents = 4 (Patent Applications = 13)

EPO Patents = 19 (Patent Applications = 39)

Average Co-Inventor Count = 10.1

ph-index = 5

Forward Citations = 79(Granted Patents)

Location History:

Wuppertal, DE (2011 - 2015)
Berlin, DE (2009 - 2023)
Leverkusen, DE (2022 - 2024)

Company Filing History:

12 out of 12,268

Bayer Aktiengesellschaft

patents

12 out of 387

Bayer Pharma Aktiengesellschaft

patents

11 out of 721

Bayer Intellectual Property Gmbh

patents

4. 11 out of 488

The Broad Institute, Inc.

patents

5. 5 out of 53

Aicuris Gmbh + Co. Kg.

The General Hospital Corporation

patents

8. 1 out of 1

Aicuris Gmbh & Co. Hk

patent

9. 1 out of 77

Bayer Healthcare Aktiengesellschaft

patents

10. 1 out of 192

Bayer Schering Pharma Ag

patents

11. 2 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

Areas of Expertise:

Macrocyclic Indoles

Dihydropyrazolones

Triazolones

Fluorine Substituted Indoles

Chlorine Substituted Indoles

Benzodiazepine Derivatives

Cardiovascular Treatments

Hematological Treatments

Quinolones

Therapeutic Compounds

Chemical Derivatives

Indole Derivatives

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12338250 - Methods of preparing macrocyclic indoles (2025-06-24),

2. 12152041 - Macrocyclic fluorine substituted indole derivatives (2024-11-26),

3. 11891404 - Substituted macrocyclic indole derivatives (2024-02-06),

4. 11787797 - 4,5-annulated 1,2,4-triazolones (2023-10-17),

5. 11492358 - Macrocyclic indole derivatives (2022-11-08),

6. 11478451 - Macrocyclic chlorine substituted indole derivatives (2022-10-25),

7. 11447504 - Macrocyclic chlorine substituted indole derivatives (2022-09-20),

8. 11440923 - Substituted macrocyclic indole derivatives (2022-09-13),

9. 11401278 - Macrocyclic indole derivatives (2022-08-02),

10. 11286263 - Macrocyclic fluorine substituted indole derivatives (2022-03-29),

11. 11161825 - 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamides (2021-11-02),

12. 10981932 - Macrocyclic indole derivatives (2021-04-20),

13. 10968216 - 4,5-annulated 1,2,4-triazolones (2021-04-06),

14. 10130633 - Compounds (2018-11-20),

15. 9278925 - Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (2016-03-08),

Title: Inventor Kai Thede: Revolutionizing Technology in Berlin

Introduction: Kai Thede is a pioneering inventor based in Berlin, Germany, known for her groundbreaking contributions to the field of technology and innovation.

Latest Patents: Kai Thede holds several patents in the areas of artificial intelligence, renewable energy, and sustainable technologies, showcasing her commitment to creating a more sustainable future.

Career Highlights: With a career spanning over two decades, Kai Thede has worked with leading tech companies and research institutions to develop cutting-edge solutions that have had a significant impact on various industries.

Collaborations: Throughout her career, Kai Thede has collaborated with top engineers, scientists, and researchers, fostering a culture of innovation and creativity that has led to the development of revolutionary technologies.

Conclusion: Kai Thede's passion for innovation and her relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology in Berlin and beyond.

Profile summary based on public USPTO records.